Nevertheless, in terms of precision medicine, HER2-targeted treatments should be given to patients after confirming HER2 expression in bone metastases, not relying on the initial diagnosis, which is based on HER2 expression evaluation of the primary tumor. This evidence concerns the gene ERBB2 and neoplasm.